Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

Rhea-AI Summary

Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory disease treatments, has announced its participation in the HC Wainwright "HCW@Home" virtual series. The company's CEO Neal Walker and senior leadership team will engage in a fireside chat scheduled for May 16, 2025, at 1:00 PM EDT. Investors and interested parties can access the live webcast and a 30-day replay through the Events page on the company's website at aclaristx.com.

WAYNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Aclaris’ Chief Executive Officer Neal Walker and other members of the Aclaris senior leadership team will participate in a fireside chat during the virtual HC Wainwright “HCW@Home” series.

The virtual fireside chat will take place on Friday May 16, 2025, at 1:00 PM EDT. A live and archived webcast of the event will be accessible on the Events page of https://www.aclaristx.com/. The webcast will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn.

Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com

FAQ

When is Aclaris Therapeutics (ACRS) presenting at the HC Wainwright conference?

Aclaris Therapeutics will participate in a fireside chat during the HC Wainwright 'HCW@Home' series on Friday, May 16, 2025, at 1:00 PM EDT.

Who will represent Aclaris Therapeutics (ACRS) at the HC Wainwright conference?

CEO Neal Walker and other members of the Aclaris senior leadership team will represent the company at the conference.

How can investors access Aclaris Therapeutics' (ACRS) HC Wainwright presentation?

Investors can access both the live and archived webcast through the Events page on Aclaris' website (aclaristx.com). The replay will be available for at least 30 days.

What is Aclaris Therapeutics' (ACRS) main business focus?

Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases.